1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`
`››
`
`Go to Healthcare
`Professionals site
`
`This information is for
`Patients & Caregivers
`
`Register for HERConnection
`
`View Full Prescribing Information
`
`What is KADCYLA?
`
`How can
`KADCYLA help?
`
`What can I expect
`while on KADCYLA?
`
`Are there financial
`assistance programs?
`
`What other types of
`support are there?
`
`What is KADCYLA?
`
`Safety First!
`Before you start exploring, please read
`side effect information. ›› View now
`
`How KADCYLA is thought to work
`
`Step 1: KADCYLA attaches to a HER2 receptor
`
`KADCYLA is made to find HER2-
`positive cells and attach to them. It
`tells the cells to stop growing and tells
`the body’s immune system to destroy
`them.
`
`Replay
`
`Step 1
`
`Step 2
`
`Step 3
`
`Step 4
`
`Next: See how KADCYLA can help
`
`IN THIS SECTION
`
`What is KADCYLA?
`
`› Understanding HER2+ MBC
`
`› How KADCYLA is different
`
`How KADCYLA is
`thought to work
`
`KADCYLA PATIENT SUPPORT HOTLINE
`
`Call the KADCYLA Support Line
`1 (855) KADCYLA
`or 1 (855) 523-2952
`
`››
`
`Learn more
`
`Frequently
`Asked
`Questions
`
`4HER Patient Support App
`Who is KADCYLA for?
`KADCYLA Patient Support Line
`1 (855) KADCYLA (523-2952)
`For women with HER2+ Breast Cancer ›
`Free program for patients receiving KADCYLA ›
`KADCYLA®
` is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast
`cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial
`treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
`Important Safety Information
`What is the most important safety information I should know about KADCYLA?
`
`KADCYLA is not the same medicine as trastuzumab (Herceptin).
`
`Liver problems
`
`KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include
`vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching
`
`Heart problems
`
`KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with
`symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath,
`cough, rapid weight gain of greater than 5 lbs in less than 24 hours, dizziness or loss of consciousness, or irregular
`heartbeat
`
`Pregnancy
`
`Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should
`be used while you receive KADCYLA and for 6 months after your last dose of KADCYLA
`
`http://www.kadcyla.com/about/how­it­works
`
`1/3
`
`IMMUNOGEN 2339, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`If you are exposed to KADCYLA during pregnancy, contact your healthcare provider right away; you are also encouraged
`to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720
`If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or
`stopping KADCYLA
`
`Contact your doctor right away if you experience symptoms associated with these side effects.
`What are the additional possible serious side effects of KADCYLA?
`
`Lung problems
`
`KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of
`lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs
`
`Infusion-related reactions
`
`Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing),
`chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways,
`or a fast heartbeat. Your doctor will monitor you for infusion-related reactions
`
`Serious Bleeding
`
`KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood
`(antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide
`additional monitoring if you are taking one of these other drugs while on KADCYLA. Life-threatening bleeding may also
`happen with KADCYLA even when blood thinners are not also being taken
`
`Low platelet count
`
`Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets
`may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms
`
`Nerve damage
`
`Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle
`weakness, or loss of muscle function
`
`Skin reactions around the infusion site
`
`KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or
`swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion
`How will my doctor know if KADCYLA is right for me?
`
`You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been
`shown only in patients whose tumors are HER2-positive.
`What are the most common side effects of KADCYLA?
`
`The most common side effects seen in people taking KADCYLA are:
`
`Tiredness
`Nausea
`Pain that affects the bones, muscles, ligaments, and tendons
`Bleeding
`Low platelet count
`Headache
`Liver problems
`Constipation
`Nosebleeds
`
`You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555.
`You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
`
`Please see KADCYLA full Prescribing Information, including Most Important Safety Information, for additional Important Safety
`Information.
`
`Home
`Contact Us
`Site Map
`Important Safety Information
`Privacy Policy
`Terms and Conditions
`© 2015 Genentech USA, Inc. All rights reserved. This site is intended for US residents only.
`
`http://www.kadcyla.com/about/how­it­works
`
`2/3
`
`IMMUNOGEN 2339, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`
`http://www.kadcyla.com/about/how­it­works
`
`3/3
`
`IMMUNOGEN 2339, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`
`››
`
`Go to Healthcare
`Professionals site
`
`This information is for
`Patients & Caregivers
`
`Register for HERConnection
`
`View Full Prescribing Information
`
`What is KADCYLA?
`
`How can
`KADCYLA help?
`
`What can I expect
`while on KADCYLA?
`
`Are there financial
`assistance programs?
`
`What other types of
`support are there?
`
`What is KADCYLA?
`
`Safety First!
`Before you start exploring, please read
`side effect information. ›› View now
`
`How KADCYLA is thought to work
`
`Step 2: KADCYLA goes inside the cell
`
`KADCYLA also goes inside the cell to
`keep fighting from the inside.
`
`Replay
`
`Step 1
`
`Step 2
`
`Step 3
`
`Step 4
`
`Next: See how KADCYLA can help
`
`IN THIS SECTION
`
`What is KADCYLA?
`
`› Understanding HER2+ MBC
`
`› How KADCYLA is different
`
`How KADCYLA is
`thought to work
`
`KADCYLA PATIENT SUPPORT HOTLINE
`
`Call the KADCYLA Support Line
`1 (855) KADCYLA
`or 1 (855) 523-2952
`
`››
`
`Learn more
`
`Frequently
`Asked
`Questions
`
`4HER Patient Support App
`Who is KADCYLA for?
`KADCYLA Patient Support Line
`1 (855) KADCYLA (523-2952)
`For women with HER2+ Breast Cancer ›
`Free program for patients receiving KADCYLA ›
`KADCYLA®
` is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast
`cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial
`treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
`Important Safety Information
`What is the most important safety information I should know about KADCYLA?
`
`KADCYLA is not the same medicine as trastuzumab (Herceptin).
`
`Liver problems
`
`KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include
`vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching
`
`Heart problems
`
`KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with
`symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath,
`cough, rapid weight gain of greater than 5 lbs in less than 24 hours, dizziness or loss of consciousness, or irregular
`heartbeat
`
`Pregnancy
`
`Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should
`be used while you receive KADCYLA and for 6 months after your last dose of KADCYLA
`
`http://www.kadcyla.com/about/how­it­works
`
`1/3
`
`IMMUNOGEN 2339, pg. 4
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`If you are exposed to KADCYLA during pregnancy, contact your healthcare provider right away; you are also encouraged
`to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720
`If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or
`stopping KADCYLA
`
`Contact your doctor right away if you experience symptoms associated with these side effects.
`What are the additional possible serious side effects of KADCYLA?
`
`Lung problems
`
`KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of
`lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs
`
`Infusion-related reactions
`
`Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing),
`chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways,
`or a fast heartbeat. Your doctor will monitor you for infusion-related reactions
`
`Serious Bleeding
`
`KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood
`(antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide
`additional monitoring if you are taking one of these other drugs while on KADCYLA. Life-threatening bleeding may also
`happen with KADCYLA even when blood thinners are not also being taken
`
`Low platelet count
`
`Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets
`may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms
`
`Nerve damage
`
`Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle
`weakness, or loss of muscle function
`
`Skin reactions around the infusion site
`
`KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or
`swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion
`How will my doctor know if KADCYLA is right for me?
`
`You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been
`shown only in patients whose tumors are HER2-positive.
`What are the most common side effects of KADCYLA?
`
`The most common side effects seen in people taking KADCYLA are:
`
`Tiredness
`Nausea
`Pain that affects the bones, muscles, ligaments, and tendons
`Bleeding
`Low platelet count
`Headache
`Liver problems
`Constipation
`Nosebleeds
`
`You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555.
`You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
`
`Please see KADCYLA full Prescribing Information, including Most Important Safety Information, for additional Important Safety
`Information.
`
`Home
`Contact Us
`Site Map
`Important Safety Information
`Privacy Policy
`Terms and Conditions
`© 2015 Genentech USA, Inc. All rights reserved. This site is intended for US residents only.
`
`http://www.kadcyla.com/about/how­it­works
`
`2/3
`
`IMMUNOGEN 2339, pg. 5
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`
`http://www.kadcyla.com/about/how­it­works
`
`3/3
`
`IMMUNOGEN 2339, pg. 6
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`
`››
`
`Go to Healthcare
`Professionals site
`
`This information is for
`Patients & Caregivers
`
`Register for HERConnection
`
`View Full Prescribing Information
`
`What is KADCYLA?
`
`How can
`KADCYLA help?
`
`What can I expect
`while on KADCYLA?
`
`Are there financial
`assistance programs?
`
`What other types of
`support are there?
`
`What is KADCYLA?
`
`Safety First!
`Before you start exploring, please read
`side effect information. ›› View now
`
`How KADCYLA is thought to work
`
`Step 3: Breaks apart inside the cell
`
`KADCYLA releases the chemotherapy
`inside the cell.
`
`Replay
`
`Step 1
`
`Step 2
`
`Step 3
`
`Step 4
`
`Next: See how KADCYLA can help
`
`IN THIS SECTION
`
`What is KADCYLA?
`
`› Understanding HER2+ MBC
`
`› How KADCYLA is different
`
`How KADCYLA is
`thought to work
`
`KADCYLA PATIENT SUPPORT HOTLINE
`
`Call the KADCYLA Support Line
`1 (855) KADCYLA
`or 1 (855) 523-2952
`
`››
`
`Learn more
`
`Frequently
`Asked
`Questions
`
`4HER Patient Support App
`Who is KADCYLA for?
`KADCYLA Patient Support Line
`1 (855) KADCYLA (523-2952)
`For women with HER2+ Breast Cancer ›
`Free program for patients receiving KADCYLA ›
`KADCYLA®
` is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast
`cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial
`treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
`Important Safety Information
`What is the most important safety information I should know about KADCYLA?
`
`KADCYLA is not the same medicine as trastuzumab (Herceptin).
`
`Liver problems
`
`KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include
`vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching
`
`Heart problems
`
`KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with
`symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath,
`cough, rapid weight gain of greater than 5 lbs in less than 24 hours, dizziness or loss of consciousness, or irregular
`heartbeat
`
`Pregnancy
`
`Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should
`be used while you receive KADCYLA and for 6 months after your last dose of KADCYLA
`
`http://www.kadcyla.com/about/how­it­works
`
`1/3
`
`IMMUNOGEN 2339, pg. 7
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`If you are exposed to KADCYLA during pregnancy, contact your healthcare provider right away; you are also encouraged
`to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720
`If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or
`stopping KADCYLA
`
`Contact your doctor right away if you experience symptoms associated with these side effects.
`What are the additional possible serious side effects of KADCYLA?
`
`Lung problems
`
`KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of
`lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs
`
`Infusion-related reactions
`
`Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing),
`chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways,
`or a fast heartbeat. Your doctor will monitor you for infusion-related reactions
`
`Serious Bleeding
`
`KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood
`(antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide
`additional monitoring if you are taking one of these other drugs while on KADCYLA. Life-threatening bleeding may also
`happen with KADCYLA even when blood thinners are not also being taken
`
`Low platelet count
`
`Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets
`may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms
`
`Nerve damage
`
`Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle
`weakness, or loss of muscle function
`
`Skin reactions around the infusion site
`
`KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or
`swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion
`How will my doctor know if KADCYLA is right for me?
`
`You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been
`shown only in patients whose tumors are HER2-positive.
`What are the most common side effects of KADCYLA?
`
`The most common side effects seen in people taking KADCYLA are:
`
`Tiredness
`Nausea
`Pain that affects the bones, muscles, ligaments, and tendons
`Bleeding
`Low platelet count
`Headache
`Liver problems
`Constipation
`Nosebleeds
`
`You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555.
`You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
`
`Please see KADCYLA full Prescribing Information, including Most Important Safety Information, for additional Important Safety
`Information.
`
`Home
`Contact Us
`Site Map
`Important Safety Information
`Privacy Policy
`Terms and Conditions
`© 2015 Genentech USA, Inc. All rights reserved. This site is intended for US residents only.
`
`http://www.kadcyla.com/about/how­it­works
`
`2/3
`
`IMMUNOGEN 2339, pg. 8
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`
`http://www.kadcyla.com/about/how­it­works
`
`3/3
`
`IMMUNOGEN 2339, pg. 9
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`
`››
`
`Go to Healthcare
`Professionals site
`
`This information is for
`Patients & Caregivers
`
`Register for HERConnection
`
`View Full Prescribing Information
`
`What is KADCYLA?
`
`How can
`KADCYLA help?
`
`What can I expect
`while on KADCYLA?
`
`Are there financial
`assistance programs?
`
`What other types of
`support are there?
`
`What is KADCYLA?
`
`Safety First!
`Before you start exploring, please read
`side effect information. ›› View now
`
`How KADCYLA is thought to work
`
`Step 4: Works to help kill the cell
`
`The chemotherapy goes to work inside
`the cell, causing the cell to die.
`
`Replay
`
`Step 1
`
`Step 2
`
`Step 3
`
`Step 4
`
`Next: See how KADCYLA can help
`
`IN THIS SECTION
`
`What is KADCYLA?
`
`› Understanding HER2+ MBC
`
`› How KADCYLA is different
`
`How KADCYLA is
`thought to work
`
`KADCYLA PATIENT SUPPORT HOTLINE
`
`Call the KADCYLA Support Line
`1 (855) KADCYLA
`or 1 (855) 523-2952
`
`››
`
`Learn more
`
`Frequently
`Asked
`Questions
`
`4HER Patient Support App
`Who is KADCYLA for?
`KADCYLA Patient Support Line
`1 (855) KADCYLA (523-2952)
`For women with HER2+ Breast Cancer ›
`Free program for patients receiving KADCYLA ›
`KADCYLA®
` is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast
`cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial
`treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
`Important Safety Information
`What is the most important safety information I should know about KADCYLA?
`
`KADCYLA is not the same medicine as trastuzumab (Herceptin).
`
`Liver problems
`
`KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include
`vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching
`
`Heart problems
`
`KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with
`symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath,
`cough, rapid weight gain of greater than 5 lbs in less than 24 hours, dizziness or loss of consciousness, or irregular
`heartbeat
`
`Pregnancy
`
`Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should
`be used while you receive KADCYLA and for 6 months after your last dose of KADCYLA
`
`http://www.kadcyla.com/about/how­it­works
`
`1/3
`
`IMMUNOGEN 2339, pg. 10
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`If you are exposed to KADCYLA during pregnancy, contact your healthcare provider right away; you are also encouraged
`to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720
`If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or
`stopping KADCYLA
`
`Contact your doctor right away if you experience symptoms associated with these side effects.
`What are the additional possible serious side effects of KADCYLA?
`
`Lung problems
`
`KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of
`lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs
`
`Infusion-related reactions
`
`Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing),
`chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways,
`or a fast heartbeat. Your doctor will monitor you for infusion-related reactions
`
`Serious Bleeding
`
`KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood
`(antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide
`additional monitoring if you are taking one of these other drugs while on KADCYLA. Life-threatening bleeding may also
`happen with KADCYLA even when blood thinners are not also being taken
`
`Low platelet count
`
`Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets
`may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms
`
`Nerve damage
`
`Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle
`weakness, or loss of muscle function
`
`Skin reactions around the infusion site
`
`KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or
`swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion
`How will my doctor know if KADCYLA is right for me?
`
`You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been
`shown only in patients whose tumors are HER2-positive.
`What are the most common side effects of KADCYLA?
`
`The most common side effects seen in people taking KADCYLA are:
`
`Tiredness
`Nausea
`Pain that affects the bones, muscles, ligaments, and tendons
`Bleeding
`Low platelet count
`Headache
`Liver problems
`Constipation
`Nosebleeds
`
`You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555.
`You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
`
`Please see KADCYLA full Prescribing Information, including Most Important Safety Information, for additional Important Safety
`Information.
`
`Home
`Contact Us
`Site Map
`Important Safety Information
`Privacy Policy
`Terms and Conditions
`© 2015 Genentech USA, Inc. All rights reserved. This site is intended for US residents only.
`
`http://www.kadcyla.com/about/how­it­works
`
`2/3
`
`IMMUNOGEN 2339, pg. 11
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`1/21/2015
`
`How KADCYLA® (ado­trastuzumab emtansine) Works to Target HER2
`
`http://www.kadcyla.com/about/how­it­works
`
`3/3
`
`IMMUNOGEN 2339, pg. 12
`Phigenix v. Immunogen
`IPR2014-00676
`
`